At the European Academy of Dermatology and Venereology (EADV) Congress 2026, Johnson & Johnson shared groundbreaking late-breaking clinical data from its Phase 3 ICONIC-TOTAL study. The long-term evaluation confirmed that ICOTYDE (icotrokinra), the industry’s first targeted oral peptide blocking the IL-23 receptor, provides durable skin clearance through 112 weeks of therapy. The medication demonstrated persistent efficacy on difficult-to-treat, high-impact plaque psoriasis sites—including the scalp, genitals, hands, and feet—offering patients a highly scalable systemic alternative to painful injections and messy creams.
About the Author
